Drug results: 2
| mecasermin | Recombinant form of endogenous Insulin-like Growth Factor 1 exhibiting mitogenic activity. Clinical Use: Diabetes Mellitus and Amyotrophic Lateral Sclerosis. | |
| mecasermin rinfabate | Mecasermin rinfabate [rDNA origin] injection is an aqueous solution for injection containing a binary protein complex of human insulin-like growth factor-1 (rhIGF-1) and human insulin-like growth factor-binding protein-3 (rhIGFBP-3), both produced by recombinant DNA technology. The primary pharmacologic effect of IGF-1 in children is the promotion of linear growth. Secondary pharmacologic actions of IGF-1 include other anabolic effects, insulin sensitization, and insulin-like effects. There are no known direct growth-promoting effects of IGFBP-3. The primary effect of IGFBP-3 in the mecasermin rinfabate complex is the modulation of IGF-1 action. |








Citing DrugCentral © 2026.
License